Abstract
We evaluated the toxicity of high-dose local interleukin-2 (IL-2) in 18 patients not eligible for standard treatment of advanced transitional cell bladder carcinoma. Seven received continuous high-dose local natural IL-2 via pump system in the bladder for up to 420 days. 11 received cyclic high-dose local natural IL-2 or recombinant IL-2 for up to 420 days. Treatment was well tolerated and, considering the low rate of toxicity, could be offered in an outpatient setting. Except for local contrast-media hypersensitivity, no serious side-effects were observed. This study provides a basis for the non-toxic use of local IL-2 in future studies to evaluate effectiveness of the treatment or prophylaxis of patients with superficial bladder cancer in order to prevent recurrences.
Key words: Interleukin-2, Intravesical instillation, Bladder carcinoma
Abbreviations
- IL-2
interleukin-2
- TUR
transurethral resection
- TNFα
tumor necrosis factor α
Footnotes
This study was supported by the Deutsche Forschungsgemeinschaft
References
- Bradley LM, Duncan DD, Tonkonogy S, Swain SL (1991) Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL-14−, CD45 RB− helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma. J Exp Med 174:547–559 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Heinzer H, Huland H, Huland E (1990) Activated eosinophil leucocytes in interleukin-2 treated patients: evidence for a new antitumor effector mechanism (abstract). J Cancer Res Clin Oncol 369
- Herr H (1987) Conservative management of muscle-infiltrating bladder cancer: prospective Experience. J Urol 138:1162–1163 [DOI] [PubMed] [Google Scholar]
- Huland E, Huland H (1989) Local continuous high dose interleukin-2: a new therapeutic model for the treatment of advanced bladder carcinoma. Cancer Res 49:5469–5474 [PubMed] [Google Scholar]
- Huland E, Huland H (1992) Tumor associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118:463–467 [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huland E, Heinzer H, Huland H (1991) Increase toxicity to local and systemic n-Interleukin-2 (nIL-2) after iodine-containing radiographic contrast media (ICCM). J Urol 145:334 [Google Scholar]
- Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147:3443–3448 [DOI] [PubMed] [Google Scholar]
- Lee RE, Lotze MT, Skibber JM, Tucker E, Bonow RO, Ognibene FP, Carrasquillo JA, Shelhamer JH, Parrillo JE, Rosenberg SA (1989) Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7:7–20 [DOI] [PubMed] [Google Scholar]
- Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986a) High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment related morbidity, and histological findings. JAMA 256:3117–3124 [PubMed] [Google Scholar]
- Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA, Rosenberg SA (1986b) Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 12:2764–2772 [DOI] [PubMed] [Google Scholar]
- Mertelsmann R, Welte K (1986) Human interleukin-2: molecular biology, physiology and clinical possibilities. Immunobiology 172:400–419 [DOI] [PubMed] [Google Scholar]
- Sosnowski JT, De Haven JI, Abraham FM, Riggs DR, Lamm DL (1992) Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guérin and interleukin-2 immunotherapy. J Urol 147:1439–1443 [DOI] [PubMed] [Google Scholar]
- Wang MH, Flad HD, Böhle A, Chen YQ, Ulmer AJ (1991) Cellular cytoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol Lett 27:191–197 [DOI] [PubMed] [Google Scholar]
- West WH, Tauer KW, Yannelli, JR, Marshall GD, Orr DW, Thurmann GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905 [DOI] [PubMed] [Google Scholar]